Clinically studied UK GMP Launch preparation

Commercial opportunity · Launch preparation

From scientificprogramme tocommercial opportunity.

T-Booster brings together four years of R&D, an 18-ingredient formulation, UK GMP manufacturing and completed participation in two controlled human studies. The commercial phase now focuses on evidence completion, market preparation, channel access and disciplined validation before wider scale.

Explore the opportunity View the growth model
T-Booster bottle
260HEALTHY ADULTS
2CONTROLLED STUDIES
66,000UK GMP CAPSULES
£700K+INVESTED

01 · Market context

A growing categorymakes room to focus.

The cited immune-health supplements market was US$86B in 2024 and is forecast to reach US$132B by 2028. For T-Booster, the opportunity starts with that category headroom, then narrows towards defined markets, channels and a disciplined early-entry plan.

2024 market size US$86B
2028 forecast US$132B

Source cited in the investor deck: Stratview Research, Immune Health Supplements Market. Only the reported endpoint figures are presented here.

02 · Focused market entry

The market is focusedbefore it scales.

T-Booster’s planning separates total category scale from a serviceable market and a deliberately constrained early-entry opportunity. The objective is not to treat the whole immune-health market as immediately accessible.

01TAMTotal Addressable Market
US$86B
02SAMServiceable Addressable Market
US$15B
03SOMFocused early-entry subset
US$48M

Priority markets

UK · USA · EU · Bangladesh

Commercial routes

Direct-to-consumer, distribution, specialist retail and practitioner channels form the current route set.

The stated SOM is a focused early-entry subset of the stated SAM.

03 · Commercial foundation

A new phase beginson firm groundwork.

Four years of R&D, an 18-ingredient formulation and UK GMP production are supported by completed human-study participation. Commercial preparation is therefore building on an established development programme rather than an early-stage idea.

Research4 years

T-Booster R&D programme.

Formulation18

Selected compounds.

Manufacturing66,000

UK GMP capsules produced.

Human programme260

Healthy adults · 2 studies.

Current phaseNow

Commercial preparation.

01

Evidence-led foundation

Two controlled studies involving 260 healthy adults provide a developed human-research foundation while final analysis and interpretation remain subject to the evidence process.

02

Manufacturing learning

A 66,000-capsule UK GMP production run has generated practical formulation, quality and production experience ahead of commercial scale-up.

03

Commercial flexibility

The proposition can be tested through direct sales, distribution, specialist retail and practitioner routes, supported by scientific leadership and market-specific preparation.

Position today: substantial development groundwork has been completed, but regulatory, market, financing and execution risk remain.

04 · Route to market

Prepare. Activate.Validate. Then scale.

Commercial expansion follows evidence and operating readiness, with each stage guided by demonstrated market performance rather than assumptions alone.

01 Prepare

Launch readiness

Complete evidence, claims, labelling and launch-market readiness.

Evidence and compliance
02 Activate

Demand and delivery

Coordinate demand, manufacturing and distribution for a controlled launch.

Current execution stage
03 Validate

Validate, then scale

Test acquisition, repeat purchase and channel economics before expansion.

Evidence-led expansion

Commercial engine

Investment acceleratescommercial execution.

The scientific, manufacturing and human-study foundations are already established. Investment is intended to accelerate launch preparation and market execution.

01Brand and demand

Positioning, creative and customer acquisition.

02Supply readiness

Manufacturing, inventory and fulfilment.

03Channel access

Direct, distribution and specialist routes.

04Launch intelligence

Acquisition, retention and unit economics.

05 · Development platform

Capabilities transfer.Conclusions do not.

T-Booster has assembled scientific screening and AI/ML-assisted formulation, alongside UK GMP, CRO/CMO relationships and established study operations. That infrastructure can support future targeted concepts, while each one still requires its own formulation, testing and validation.

Established capability base T-Booster clinical-development engine

Operational learning can shorten the path from a research question to a properly tested future concept.

  1. 01
    Identify trial signals

    Use participant-reported outcomes and study data to define hypotheses worth investigating.

  2. 02
    Targeted formulations

    Apply the existing literature, AI/ML and formulation workflow to create focused concepts.

  3. 03
    Manufacture to GMP

    Reuse supplier knowledge, UK GMP relationships and production learning where appropriate.

  4. 04
    Run focused studies

    Build on established recruitment, coordination, data-capture and operational experience.

  5. 05
    Decide from evidence

    Use new data to progress, refine or stop each concept before significant commercial scale.

Pipeline signals

Signals for future hypotheses—not future product claims.

Among participants who reported the relevant concern at baseline, the following proportions reported improvement after four months. These participant-reported outcomes are signals for future investigation, not proof of efficacy for a future product.

68%reported improved skin healthPotential concept: T-Booster Skin
80%reported better sleep qualityPotential concept: T-Booster Sleep
76%reported improved urinary healthPotential concept: T-Booster Men
75%reported higher energy levelsPotential concept: T-Booster Energy

Each future concept would require its own formulation, protocol, safety review, testing, claims assessment and validation before launch. The strategic advantage is reusable operational infrastructure and learning—not automatic clinical proof.

06 · Illustrative growth model

Planning assumptionscompound over time.

This management model connects projected consumers, annual use and an illustrative net-profit margin to show one possible scale pathway. It is a planning scenario, not a valuation or a guarantee.

Planned monthly price£19.99per month
Modeled annual use8 monthsper consumer
Annual revenue per consumer£159.92planning assumption
Modeled net-profit margin~20%planning assumption

Seven-year investment model

Gross revenue with net profit shown by year.

Gross revenueNet profit portion

Model driver: 50% modeled annual consumer growth, £19.99 monthly pricing and eight months of modeled annual use.

Detailed financial assumptions, marketing plans, channel strategy and supporting commercial data are available privately to prospective investors.

Important: These are illustrative management projections based on current commercial planning assumptions, not guarantees. Actual outcomes may differ materially due to execution, evidence, regulatory, financing, supply, pricing and market factors.

Private discussion

Build T-Booster’s next stage.

Strategic investors and commercial partners can request detailed launch plans and supporting commercial data privately.

Request investor discussion